An updated December 2025 ERS clinical practice guideline provides evidence-based recommendations for managing adult ...

Brensocatib, the first FDA-approved medication to treat non-cystic fibrosis bronchiectasis, can reduce symptoms of the chronic lung condition by targeting inflammation.

Add Yahoo as a preferred source to see more of our stories on Google. Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 ...

The Medicines and Healthcare products Regulatory Agency has granted marketing authorisation for brensocatib, branded as Brinsupri, marking the first time a medicine specifically designed to treat ...

The MHRA has licensed brensocatib as the first disease-specific therapy for non-cystic fibrosis bronchiectasis in patients with recurrent exacerbations.

Bronchiectasis is a chronic condition of the respiratory system, in which there is abnormal widening of the airways due to an initial damaging factor. This in turn reduces the ability of the bronchi ...

Bronchiectasis is a chronic condition of the respiratory system that is due to abnormal widening of the airways as a consequence of an initial damaging factor. The bronchi, located between the trachea ...

Panelists discuss how future bronchiectasis research will focus on precision medicine, identify treatable traits, and expand networks of Centers of Excellence to provide advanced care and clinical ...

While bronchiectasis is an old condition, it is only in the last decade that there have been major strides in our understanding of this disease and its treatment. Recent evidence has shown that the ...

Smoking, pulmonary hypertension, and a decline in lung function are associated with an increased risk of death in people with chronic obstructive pulmonary disease (COPD). Now researchers in Spain ...

Dublin, Dec. 09, 2024 (GLOBE NEWSWIRE) -- The "Bronchiectasis - Market Insight, Epidemiology and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report ...

BRONCHIECTASIS is protean in its expressions as it is sometimes obscure in its origin. The clinical picture varies in individual patients, but common to the severer cases is a history of harassing, ...